Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/1/2025

Imeglimin and Metformin Combination Therapy in Type 2 Diabetes

Guideline Recommendations

  • The American College of Physicians strongly recommends adding SGLT-2 inhibitors or GLP-1 agonists to metformin to reduce all-cause mortality, major adverse cardiovascular events, and hospitalization for heart failure 1, 2
  • The American Diabetes Association recommends SGLT-2 inhibitors for patients with heart failure or chronic kidney disease, and GLP-1 agonists for those with increased stroke risk or weight loss goals, independent of A1C levels 3
  • DPP-4 inhibitors receive a strong recommendation against adding to metformin for reducing morbidity and mortality (high-certainty evidence) 1

Positioning Imeglimin in Treatment Algorithms

  • Imeglimin represents a reasonable option when patients cannot tolerate or have contraindications to first-line add-on agents (SGLT-2 inhibitors, GLP-1 agonists) 2
  • Imeglimin should not be prioritized over SGLT-2 inhibitors or GLP-1 agonists in patients with established atherosclerotic cardiovascular disease 3, heart failure (reduced or preserved ejection fraction) 1, chronic kidney disease with eGFR ≥30 mL/min/1.73 m² 3, or high cardiovascular risk or history of stroke 2

Monitoring Requirements

  • Assess A1C within 3 months of initiating combination therapy to evaluate glycemic response 3
  • Continue periodic vitamin B12 monitoring with long-term metformin use, as metformin is associated with deficiency and worsening neuropathy 3

Critical Caveats

  • Imeglimin lacks cardiovascular and renal outcome trial data demonstrating mortality or morbidity benefits, unlike SGLT-2 inhibitors and GLP-1 agonists which have robust evidence for reducing death, cardiovascular events, and kidney disease progression 1, 2, 3
  • If glycemic control remains inadequate on metformin-imeglimin combination, strongly consider switching to or adding an SGLT-2 inhibitor or GLP-1 agonist rather than further intensification with agents lacking mortality benefits 1, 3